Terms: = Liver cancer AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Prognosis
21 results:
1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
2. OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway.
Ci M; Zhao G; Li C; Liu R; Hu X; Pan J; Shen Y; Zhang G; Li Y; Zhang L; Liang P; Cui H
Cell Death Dis; 2024 Mar; 15(3):179. PubMed ID: 38429268
[TBL] [Abstract] [Full Text] [Related]
3. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract] [Full Text] [Related]
6. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract] [Full Text] [Related]
7. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract] [Full Text] [Related]
8. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
Goeppert B; Toth R; Singer S; Albrecht T; Lipka DB; Lutsik P; Brocks D; Baehr M; Muecke O; Assenov Y; Gu L; Endris V; Stenzinger A; Mehrabi A; Schirmacher P; Plass C; Weichenhan D; Roessler S
Hepatology; 2019 May; 69(5):2091-2106. PubMed ID: 30615206
[TBL] [Abstract] [Full Text] [Related]
9. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract] [Full Text] [Related]
10. New Horizons for Precision Medicine in Biliary Tract cancers.
Valle JW; Lamarca A; Goyal L; Barriuso J; Zhu AX
Cancer Discov; 2017 Sep; 7(9):943-962. PubMed ID: 28818953
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type.
Chen J; He J; Deng M; Wu HY; Shi J; Mao L; Sun Q; Tang M; Fan XS; Qiu YD; Huang Q
Hum Pathol; 2017 Jun; 64():118-127. PubMed ID: 28431889
[TBL] [Abstract] [Full Text] [Related]
12. Emerging molecular therapeutic targets for cholangiocarcinoma.
Rizvi S; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract] [Full Text] [Related]
13. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct idh-Mutant Molecular Profiles.
Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
[TBL] [Abstract] [Full Text] [Related]
14. Genomic Profiling of Biliary Tract cancers and Implications for Clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract] [Full Text] [Related]
15. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
[TBL] [Abstract] [Full Text] [Related]
16. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.
Moeini A; Sia D; Bardeesy N; Mazzaferro V; Llovet JM
Clin Cancer Res; 2016 Jan; 22(2):291-300. PubMed ID: 26405193
[TBL] [Abstract] [Full Text] [Related]
18. Genetic variations in idh gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients.
Zhang H; Guo X; Dai J; Wu Y; Ge N; Yang Y; Ji J; Zhang H
Med Oncol; 2014 Nov; 31(11):278. PubMed ID: 25355558
[TBL] [Abstract] [Full Text] [Related]
19. Genetic variants in genes of tricarboxylic acid cycle key enzymes predict postsurgical overall survival of patients with hepatocellular carcinoma.
Du X; Wan S; Chen Y; Qu P; Huang X; Yu X; Yang H; Zhang Y; Xing J
Ann Surg Oncol; 2014 Dec; 21(13):4300-7. PubMed ID: 25081338
[TBL] [Abstract] [Full Text] [Related]
20. High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.
Liu WR; Tian MX; Jin L; Yang LX; Ding ZB; Shen YH; Peng YF; Zhou J; Qiu SJ; Dai Z; Fan J; Shi YH
J Exp Clin Cancer Res; 2014 Apr; 33(1):32. PubMed ID: 24716838
[TBL] [Abstract] [Full Text] [Related]
[Next]
